Generic drug
Gentamicin price, strengths & recalls
Pharmacies pay $4.54 for 5 mL of Gentamicin 3 mg/mL eye drops this week, and from $2.52 to $62.88 across its 5 priced strengths and forms. 23 manufacturers make it. 5 recalls are ongoing. Its official label last changed on December 19, 2023.
5 open recallsGeneric- Fair cash price
- $15.72
- Strengths
- 5
- Makers
- 23
- Updated
- Nov 11
Gentamicin price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 1 mg/mL cream | $0.8943 | $13.41 / 15 g | ||
| 3 mg/mL eye drops | $0.9073 | $4.54 / 5 mL | ||
| 10 mg/mL, 2 mL injection | Not priced this week | |||
| 40 mg/mL injection | $1.26 | $62.88 / 50 mL | ||
| 40 mg/mL, 2 mL injection | $1.26 | $2.52 / 2 mL | ||
| 0.001 mg/mg ointment | $0.7378 | $11.07 / 15 g | ||
Supply status: shortages & recalls
Recalls
Showing the 6 most relevant of 40 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Gentamicin
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
Gentamicin Injection, USP
BOXED WARNINGS
Patients treated with aminoglycosides should be under close clinical observation because of the potential toxicity associated with their use.
As with other aminoglycosides, gentamicin injection is potentially nephrotoxic. The risk of nephrotoxicity is greater in patients with impaired renal function and in those who receive high dosage of prolonged therapy.
Neurotoxicity manifested by ototoxicity, both vestibular and auditory, can occur in patients treated with gentamicin, primarily in those with pre- existing renal damage and in patients with normal renal function treated with higher doses and/or for longer periods than recommended.
Aminoglycoside-induced ototoxicity is usually irreversible. Other manifestations of neurotoxicity may include numbness, skin tingling, muscle twitching and convulsions.
Renal and eighth cranial nerve function should be closely monitored, especially in patients with known or suspected reduced renal function at onset of therapy and also in those whose renal function is initially normal but who develop signs of renal dysfunction during therapy. Urine should be examined for decreased specific gravity, increased excretion of protein and the presence of cells or casts. Blood urea nitrogen (BUN), serum creatinine or creatinine clearance should be determined periodically. When feasible, it is recommended that serial audiograms be obtained in patients old enough to be tested, particularly high-risk patients. Evidence of ototoxicity (dizziness, vertigo, tinnitus, roaring in the ears or hearing loss) or nephrotoxicity requires dosage adjustment or discontinuance of the drug. As with the other aminoglycosides, on rare occasions changes in renal and eighth cranial nerve function may not become manifest until soon after completion of therapy.
Serum concentrations of aminoglycosides should be monitored when feasible to assure adequate levels and to avoid potentially toxic levels. When monitoring gentamicin peak concentrations, dosage should be adjusted so that prolonged levels above 12 mcg/mL are avoided. When monitoring gentamicin trough concentrations, dosage should be adjusted so that levels above 2 mcg/mL are avoided. Excessive peak and/or trough serum concentrations of aminoglycosides may increase the risk of renal and eighth cranial nerve toxicity.
In the event of overdosage or toxic reactions, hemodialysis may aid in the removal of gentamicin from the blood, especially if renal function is, or becomes, compromised. The rate of removal of gentamicin is considerably lower by peritoneal dialysis than it is by hemodialysis.
In the newborn infant, exchange transfusions may also be considered.
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as cisplatin, cephaloridine, kanamycin, amikacin, neomycin, polymyxin B, colistin, paromomycin, streptomycin, tobramycin, vancomycin and viomycin, should be avoided. Other factors which may increase patient risk of toxicity are advanced age and dehydration.
The concurrent use of gentamicin with potent diuretics, such as ethacrynic acid or furosemide, should be avoided, since certain diuretics by themselves may cause ototoxicity. In addition, when administered intravenously, diuretics may enhance aminoglycoside toxicity by altering the antibiotic concentration in serum and tissue.
Aminoglycosides can cause fetal harm when administered to a pregnant woman (see WARNINGS section).
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Generic makers
- 14 approved generic applications on the market
Gentamicin questions
How much does gentamicin cost without insurance?
Pharmacies pay about $4.54 for 5 mL of gentamicin 3 mg/mL eye drops ($0.9073 per mL). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $15.72. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is gentamicin in shortage?
No shortage is reported for gentamicin right now. We check the national shortage list every day.
Has gentamicin been recalled?
40 recalls on record, 5 ongoing. Recalls name specific lots - check yours.
When did the gentamicin label last change?
The official label was last updated on December 19, 2023 (version 4). See what changed.
Talk about gentamicin
No comments yet. Questions, tips, what worked for you - start the conversation.